Related Experiment Video

Updated: Jul 10, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Cyclins and related kinases in cancer cells

Marcos Malumbres1

  • 1Cell Division and Cancer Group, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain. malumbres@cnio.es

Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|November 6, 2007
PubMed

Insights

Targeting cyclin-dependent kinases (CDKs) shows therapeutic potential for cancer. Inhibiting mitotic CDKs halts cancer cell division, offering a promising strategy for targeted cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Tumor cell proliferation is often driven by genetic/epigenetic changes in cell cycle regulators.
  • Cyclin-dependent kinases (CDKs) control cell division progression.
  • Alterations in cyclins or CDK inhibitors promote uncontrolled cancer cell growth.

Purpose of the Study:

  • To explore the therapeutic potential of inhibiting cyclin-dependent kinases (CDKs) in cancer treatment.
  • To evaluate the impact of CDK inhibition on tumor cell proliferation.

Main Methods:

  • Analysis of genetic and epigenetic alterations in cell cycle molecules.
  • Review of studies involving genetically-engineered mouse models.
  • Biochemical and genetic data integration on CDK function.

Main Results:

  • Inhibition of CDKs may offer therapeutic benefits in human cancers.
  • Interphase CDK inhibition can impede DNA replication in specific tumor cells.
  • Mitotic CDK inactivation effectively blocks cell cycle progression in mitosis.

Conclusions:

  • Targeted inhibition of CDKs presents a viable strategy for cancer therapy.
  • Understanding CDK regulation is crucial for developing novel anti-cancer treatments.
  • Combining biochemical and genetic insights will guide the development of new therapies to inhibit cancer cell proliferation.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...